Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;11(1):191-197.
doi: 10.1111/1759-7714.13240. Epub 2019 Nov 24.

Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis

Hanping Wang  1 , Xiaoxiao Guo  2 , Jiaxin Zhou  3 , Yue Li  4 , Lian Duan  5 , Xiaoyan Si  1 , Li Zhang  6 , Xiaowei Liu  7 , Mengzhao Wang  1 , Juhong Shi  1 , Li Zhang  1
Affiliations
Review

Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis

Hanping Wang et al. Thorac Cancer. 2020 Jan.

Abstract

The increasing use of immune checkpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immune checkpoint inhibitors, mainly activated T-cells, can attack normal tissues and organs in the body and lead to a variety of adverse effects. In the lung, these attacks can induce checkpoint inhibitor pneumonitis (CIP). CIP is different from known pulmonary interstitial pneumonitis, and has the potential to be fatal if not treated correctly. In this review, we summarize the characteristics of CIP and provide advice on how to manage this disease.

Keywords: Checkpoint inhibitor pneumonitis; immune checkpoint inhibitor; immune checkpoint inhibitor-related adverse effects; immunotherapy-related toxicity.

PubMed Disclaimer

References

    1. Suresh K, Naidoo J, Lin CT, Danoff S. Immune checkpoint immunotherapy for non‐small cell lung cancer (benefits and pulmonary toxicities). Chest 2018; 154 (6): 1416–23. 10.1016/j.chest.2018.08.1048. - DOI - PMC - PubMed
    1. De Velasco G, Je Y, Bosse D et al Comprehensive meta analysis of key immune‐related adverse events from CTLA‐4 and PD‐1/PD‐L1 inhibitors in cancer patients. Cancer Immunol Res 2017; 5 (4): 312–8. 10.1158/2326-6066.CIR-16-0237. - DOI - PMC - PubMed
    1. Khunger M, Rakshit S, Pasupuleti V et al Incidence of pneumonitis with use of PD‐1 and PD‐L1 inhibitors in non‐small cell lung cancer: A systematic review and meta‐analysis of trials. Chest 2017; 152 (2): 271–81. 10.1016/j.chest.2017.04.177. - DOI - PubMed
    1. Wang YC, Sh Z, Yang F et al Treatment‐related adverse events of PD‐1 and PD‐L1 inhibitors in clinical trials: A systematic review and meta‐analysis. JAMA Oncol 2019; 5 (7): 1008–19. 10.1001/jamaoncol.2019.0393. - DOI - PMC - PubMed
    1. Su Q, Zhu EC, Wu JB et al Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: A systematic review and meta‐analysis. Front Immunol 2019; 10: 108 10.3389/fimmu.2019.00108. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances